Business Description
Tango Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US87583X1090
Total Employee Number:
137Description
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.59 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.28 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 58.85 | |||||
Beneish M-Score | -1.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 23.8 | |||||
3-Year EBITDA Growth Rate | 9 | |||||
3-Year EPS without NRI Growth Rate | 10.9 | |||||
3-Year FCF Growth Rate | 3.2 | |||||
3-Year Book Growth Rate | -3.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -22.66 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.63 | |||||
9-Day RSI | 42.28 | |||||
14-Day RSI | 46.21 | |||||
3-1 Month Momentum % | 9.74 | |||||
6-1 Month Momentum % | 142.44 | |||||
12-1 Month Momentum % | 312.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 27.38 | |||||
Quick Ratio | 27.38 | |||||
Cash Ratio | 26.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.5 | |||||
Shareholder Yield % | -1.33 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -206.22 | |||||
Net Margin % | -188.15 | |||||
EBITDA Margin % | -202.5 | |||||
FCF Margin % | -250.12 | |||||
OCF Margin % | -248.37 | |||||
ROE % | -44.7 | |||||
ROA % | -34.44 | |||||
ROIC % | -197.57 | |||||
3-Year ROIIC % | 0.46 | |||||
ROC (Joel Greenblatt) % | -265.88 | |||||
ROCE % | -41.2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 55.11 | |||||
PB Ratio | 9.85 | |||||
Price-to-Tangible-Book | 9.85 | |||||
EV-to-EBIT | -34.15 | |||||
EV-to-EBITDA | -34.77 | |||||
EV-to-Forward-EBITDA | -18.22 | |||||
EV-to-Revenue | 70.42 | |||||
EV-to-Forward-Revenue | 9.63 | |||||
EV-to-FCF | -28.15 | |||||
Price-to-GF-Value | 2.72 | |||||
| Price-to-Net-Current-Asset-Value | 11.1 | |||||
| Price-to-Net-Cash | 11.48 | |||||
Earnings Yield (Greenblatt) % | -2.93 | |||||
FCF Yield % | -3.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TNGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tango Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 56.992 | ||
| EPS (TTM) ($) | -0.83 | ||
| Beta | -0.4748 | ||
| 3-Year Sharpe Ratio | 1.05 | ||
| 3-Year Sortino Ratio | 2.76 | ||
| Volatility % | 97.73 | ||
| 14-Day RSI | 46.21 | ||
| 14-Day ATR ($) | 1.942109 | ||
| 20-Day SMA ($) | 29.624 | ||
| 12-1 Month Momentum % | 312.65 | ||
| 52-Week Range ($) | 5.77 - 34.39 | ||
| Shares Outstanding (Mil) | 162.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tango Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tango Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 09:00 | In 104 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 12 days | ||
| General meeting for 2026 | 2026-06-04 09:00 | 21.47 (+0.56%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 23.50 (+0.09%) | ||
| Guidance call for 2026 | 2026-03-11 15:00 | 16.50 (+0.67%) | ||
| Annual report for 2025 | 2026-03-05 | 12.35 (+5.56%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 12.35 (+5.56%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 13:10 | 11.50 (+3.23%) | ||
| Guidance call for 2026 | 2026-02-12 14:00 | 12.61 (+0.40%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-14 12:45 | 10.44 (-1.42%) |
Show
Entries
Tango Therapeutics Inc Frequently Asked Questions
What is Tango Therapeutics Inc(TNGX)'s stock price today?
The current price of TNGX is $26.78. The 52 week high of TNGX is $34.39 and 52 week low is $5.77.
When is next earnings date of Tango Therapeutics Inc(TNGX)?
The next earnings date of Tango Therapeutics Inc(TNGX) is 2026-08-05 Est..
Does Tango Therapeutics Inc(TNGX) pay dividends? If so, how much?
Tango Therapeutics Inc(TNGX) does not pay dividend.
Guru Commentaries on NAS:TNGX
No articles.
Press Release
Articles on Tango Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers